Introduction
Carcinoid tumors are slow-growing neuroendocrine malignancies with a reported incidence of approximately 5 : 100 000 [1, 2] . They primarily arise from the enterochromaffin cells of the gastrointestinal or the pulmonary system, but can originate from a variety of bodily tissues. Because carcinoids follow an indolent course, they often remain untreated until later stages, and therefore frequently metastasize to the liver. This generally results in the carcinoid syndrome, a disease that entails the hypersecretion of an array of bioactive hormones, including serotonin, growth hormone, and gastrin [1, 2] . However, carcinoid syndrome may occur with bronchopulmonary metastases even in the absence of hepatic involvement. Patients with carcinoid syndrome usually present with debilitating symptoms including flushing, diarrhea, vomiting, abdominal pain, and tricuspid insufficiency. Localized carcinoid tumors are curable with surgery [3, 4] . However, systemic therapies for the management of metastatic carcinoids have had limited antitumor efficacy. Current mainstay therapies for carcinoids have focused on symptomatic management and chronic care [5, 6] . Therefore, there is a high demand for new targeted therapies for patients with metastatic carcinoid disease.
Recent evidence has shown the phosphoinositide 3-kinase (PI3K)/AKT pathway to be hyperactive in human carcinoid tumors. Furthermore, treatment with either an inhibitor of the PI3K/AKT pathway, such as LY294002, or a small inhibitory RNA against AKT, suppresses growth and alters the malignant phenotype of both pancreatic and bronchopulmonary human-derived carcinoid cells [7] [8] [9] . Given these findings, carcinoid tumors may be highly susceptible to the selective inhibition of AKT. Therefore, AKT may be a potential pharmacotherapeutic target.
Because competitive ATP inhibitors of AKT often bind to protein sites that are biochemically homologous and nonspecific, they have reported a high incidence of offtarget effects. In contrast, allosteric noncompetitive ATP inhibitors of AKT kinase activity have showed a much higher level of target specificity. Recently, Merck reported the results of phase I clinical trials characterizing MK-2206, an allosteric small-molecule inhibitor of AKT, for the treatment of solid tumors [10] . Similar to other noncompetitive ATP inhibitors, MK-2206 binds to a site other than the ATP-binding domain, causing conformational changes that prevent AKT localization and subsequent kinase activity [10, 11] . Along with MK-2206, several classes of small-molecule inhibitors of AKT have been described, each with varying potencies and specificities to AKT isoforms [12] .
Studies on MK-2206 indicate that it is safe, with tolerable side effects, including some reports of a grade 1-4 rash. These studies have also established pharmacologic parameters including dose-limiting toxicities, pharmacokinetics, pharmacodynamics, and alternative day dosing regimens for phase II clinical trials [10] . This drug has also been purported to possess exceptional antitumor efficacy both in vitro and in vivo as a single agent, in addition to being a potent sensitizer to a number of other chemotherapeutic agents [10, [13] [14] [15] .
In the present study, we examined the effect of MK-2206 on neuroendocrine tumor cell growth, biomarker expression, and apoptosis in both pancreatic and bronchopulmonary carcinoid cell lines.
Materials and methods

Cell culture and treatment
Human pancreatic carcinoid cancer cells (BON) were provided by Drs B. Mark Evers and Courtney M. Townsend, Jr (University of Texas Medical Branch, Galveston, Texas, USA), and bronchopulmonary carcinoid (H727) cells were purchased from the American Type Culture Collection (Manassas, Virginia, USA). BON cells were maintained in DMEM/F-12 (Life Technologies, Grand Island, New York, USA) and H727 cells were maintained in RPMI1640 (Life Technologies), supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, Missouri, USA), 100 IU/ml penicillin, and 100 mg/ml streptomycin (Life Technologies). Both cell lines were grown in a humidified atmosphere of 5% CO 2 at 371C. MK-2206 was dissolved in dimethyl sulfoxide (DMSO; Fischer Scientific, Pittsburgh, Pennsylvania, USA) and cells were treated with varying doses of MK-2206.
Cell viability
Carcinoid tumor cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) by a standard rapid colorimetric assay. BON and H727 cells were plated in 24-well plates and allowed to adhere overnight. Cells were then treated with MK-2206 in quadruplicate at each dose. Treatments lasted for up to 6 days, and were replenished after 48 h. On the day of cell viability determination, media were replaced with 250 ml of serum-free medium containing 0.5 mg/ml MTT. Plates were then incubated at 371C for 3.5 h, followed by the addition of 750 ml of DMSO, and measured at 540 nm using a spectrophotometer (mQuant; Bio-Tek Instruments, Winooski, Vermont, USA).
Immunoblot analysis
Following treatment, cells were washed in 1 Â PBS and lysed in lysis buffer (50 mmol/l Tris, 0.15 mol/l NaCl, 0.5% Na/deoxycholate, 0.1% SDS, 1% Nonidet P-40, 0.1% protease inhibitor cocktail, and 0.6 mmol/l phenylmethanesulfonyl fluoride), and the lysates were then prepared as described [16] . A bicinchoninic acid (BCA) assay (Pierce, Rockford, Illinois, USA) was used to determine the concentration of total cellular protein. Subsequently, these samples were denatured and resolved on 7, 10, or 12% SDS-PAGE gels (Invitrogen, Grand Island, New York, USA). Proteins were then transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, California, USA) and the protein-bound membranes were blocked for at least 30 min in PBS-T containing milk (1 Â PBS, 5% dry milk, 0.05% Tween 20), and then incubated overnight at 41C in their respective primary antibodies. Each antibody was diluted as follows: 1 : 2000 for mammalian achaete-scute complex-like1 (BD PharMingen, San Diego, California, USA), 1 : 3000 for chromogranin A (Zymed Laboratories, San Francisco, California, USA), and 1 : 10 000 for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Trevigen, Gaithersburg, Maryland, USA). Phosphorylated AKT ser473 , phosphorylated AKT thr308 , total AKT, total caspase-3, cleaved caspase-3, cleaved caspase-7, total-PARP, cleaved PARP, X-linked inhibitor of apoptosis (XIAP), Mcl-1, survivin, and b-actin (Cell Signaling Technology, Beverly, Massachusetts, USA) were all diluted to 1 : 1000. Following incubation in the primary antibody, membranes were washed 3 Â 5 min in PBS-T wash buffer (1 Â PBS, 0.05% Tween 20). Blots were then incubated in either horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (Cell Signaling Technology) depending on the source of the primary antibody. Membranes were washed for 3 Â 5 or 3 Â 10 min in PBS-T wash buffer. SuperSignal West Pico, Femto (Pierce), or Immunstar (Bio-Rad Laboratories) kits were then used to develop the membranes to measure the intensity of the band according to the manufacturers' instructions.
Statistical analysis
All results shown represent mean±SEM, unless specifically noted. The significance between treatments was assessed using analysis of variance testing (SPSS software version 10.0; SPSS Inc., Chicago, Illinois, USA). A P value less than 0.05 was considered significant.
Results
MK-2206 treatment inhibits cell proliferation in carcinoid cell lines in a dose-dependent manner
We examined the effect of MK-2206 on cell proliferation in two human carcinoid cell lines: pancreatic carcinoid (BON) and bronchopulmonary (H727) carcinoid cells. Cell proliferation was assessed using an MTT assay up to 6 days following MK-2206 treatment. Results indicated that growth was dose dependently decreased in both cell lines compared to the control (DMSO) treated cells. Following 2 days of MK-2206 treatment, H727 cell proliferation decreased modestly, whereas BON cells exhibited a statistically significant, dose-dependent reduction in growth. Nevertheless, cell growth was reduced to 90% in H727 cells treated with 10 mmol/l of MK-2206 (Fig. 1a) , whereas BON cells required 15 mmol/l of MK-2206 to achieve 87% growth inhibition (Fig. 1b) following 6 days of treatment.
MK-2206 alters neuroendocrine phenotype by suppressing the production of neuroendocrine-specific biomarkers of malignancy Carcinoid syndrome progression and symptomatology is largely a result of the expression and cosecretion of a number of bioactive amines, among which is chromogranin A (CgA). These biomarkers, along with high expression levels of achaete-scute complex-like1 (ASCL1), collectively lead to a poor prognosis for carcinoid patients and are routinely utilized for diagnostic purposes. Given the prognostic significance of ASCL1 and CgA, we analyzed the impact of MK-2206 on the expression of these neuroendocrine phenotypic markers. Levels of ASCL1 and CgA were significantly reduced by MK-2206 treatment in a dose-dependent manner as shown by western blot analysis of lysate extracts from MK-2206-treated H727 and BON cells (Fig. 2a and b) . Because overexpression of ASCL1 is implicated in neuroendocrine tumorigenesis, this observed suppression of ASCL1 and CgA may collectively explain the mechanism by which MK-2206 exerts its effect on carcinoid cell proliferation. Furthermore, we observed a significant reduction in levels of other bioactive markers, including Neuron Specific Enolase and Synaptophysin in H727 cells treated with MK-2206 (Fig. 2a) . These findings cumulatively suggest that MK-2206 may have the ability to alleviate symptoms of the carcinoid syndrome.
MK-2206 selectively inhibits the phosphorylation of AKT Ser473 in carcinoids
On the basis of the reported inhibitory activity of AKT by MK-2206 in other cancer types, we sought to confirm whether this agent inhibits the phosphorylation of AKT Ser473 and AKT Thr308 in carcinoid cell lines. Both H727 and BON cells were treated with MK-2206 for a given period and subsequently subjected to western bolt analysis for levels of phosphorylated AKT. We observed that MK-2206 inhibited the phosphorylation of AKT Ser473 . Interestingly, there was no significant effect on levels of phosphorylated AKT Thr308 in H727 and BON cells ( Fig. 3a and b) , indicating that MK-2206 has no effect on the upstream PI3K pathway. We have reported previously that silencing AKT expression by AKT-specific small inhibitory RNA sequences in carcinoid cells resulted in growth suppression, along with a reduction in the expression of neuroendocrine markers [8, 9] . Collectively, these data suggest that the suppressive effects of MK-2206 on growth and neuroendocrine marker expression in carcinoid cells may be due to its ability to inactivate AKT.
MK-2206 inhibits growth in carcinoid cells through the induction of apoptosis
Having observed the growth-suppressive effects of MK-2206 in H727 and BON cells, we next aimed to establish the possible cause of cytotoxicity by determining levels of molecular markers of apoptosis in treated cells. Following treatment with MK-2206 at the appropriate doses, cells were examined by western blotting for their expression levels of cleaved poly(ADP)-ribose polymerase (PARP), cleaved caspase-3, and cleaved caspase-7. It is known that during the execution of the apoptotic cascade, cleavage of PARP, a caspase-3 substrate, must precede the cleavage of caspase-3, an ICElike protease-activated response to various cytotoxic stimuli. Similarly, cleavage of caspase-7 has also been strongly regarded as a precedent to PARP cleavage in a number of stress-induced models. Therefore, the cleavage of PARP and various caspases may be reliable indicators that cells are undergoing apoptosis following external stimuli, such as exposure to MK-2206. Indeed, we observed an elevation in levels of cleaved PARP in both H727 and BON cells after MK-2206 treatment ( Fig. 4a and b) . Furthermore, we observed an increase in cleaved caspase-3 and caspase-7 in H727 cells following treatment with MK-2206 (Fig. 4a) .
MK-2206 reduces prosurvival markers Mcl-1, survivin, and X-linked inhibitor of apoptosis in carcinoid cells
To further support the mechanism of apoptotic induction following MK-2206 treatment in carcinoids, we determined the activity of various proteins responsible for evasion of apoptosis. Among these molecular components include members of the protein family defined as the inhibitors of apoptosis (IAP), which are known for their role in intervening in programmed cell death cascades by binding to caspases in order to prevent their cleavage and subsequent activation. Among the IAPs, we chose to examine the activity of XIAP and survivin, in addition to levels of the Bcl-2 family member known as induced myeloid leukemia cell differentiation protein or Mcl-1. We observed a reduction in the expression levels of XIAP, survivin, and Mcl-1 in MK-2206-treated H727 and BON cells at doses that demonstrably induced apoptosis as indicated by the cleavage of PARP and associated caspases ( Fig. 5a and b) . Control cells showed high levels of all prosurvival markers, indicating that these proteins may support cell survival.
Discussion
The urgency for new therapies for the treatment of carcinoids is underscored by the complicated nature of their management [1, 2, 6, 17] . Carcinoids are generally encountered inadvertently, and are often unresectable at the time of diagnosis. Recent efforts have focused on elucidating molecular signaling pathway derangements in GAPDH was used as a loading control. MK-2206 treatment inhibits AKT phosphorylation. The level of phosphorylated AKT at the serine 473 position was reduced, whereas phosphorylation of the auto phosphorylation site at threonine 308 was not significantly altered in H727 (a) or BON cells (b). However, the drug had no effect on the levels of total AKT in both cell lines. GAPDH was used as a loading control.
Antiproliferative effect of MK-2206 on carcinoids Somnay et al. 69 carcinoid cell lines in order to develop effective targeted therapies [17] [18] [19] [20] [21] . Among these pathways is the phosphoinositide 3-kinase (PI3K)/AKT pathway, which regulates such functions as mitogenesis, cellular motility, and protection from apoptosis in normal tissues [22, 23] . Hyperactivation of the PI3K-AKT pathway has been commonly implicated in the growth, progression, and phenotypic expression of a number of neoplasms including breast, prostate, colon, ovarian, and neuroendocrine cancers [22, 23] . The current course of drug development has attempted to exploit the critical nature of the PI3K-AKT pathway in various cancer pathogeneses using smallmolecule inhibitors of this pathway [24] .
In this study, we tested the therapeutic potential of the AKT inhibitor MK-2206 in both pancreatic and bronchopulmonary carcinoid tumor cell lines, BON and H727, respectively. We found that this drug exerts a potent and efficacious inhibitory effect on cell proliferation in both cell lines. This is aligned with reports that describe the capacity of MK-2206 to inhibit cell growth in other cancer cell lines, including thyroid cancer cells that harbor mutations in the PI3K/AKT pathway, in addition to colon cancer, gliomas, non-small-cell lung cancers, and melanomas [13, 15] . Our studies further found that this observed antitumor effect of MK-2206 correlates with a reduction in AKT phosphorylation at the serine 473 residue in both BON and H727 cells. Furthermore, we found that the effects of this drug were associated with the inhibition of ASCL1, CgA, SYP, and NSE production, neuroendocrine biomarkers that can be utilized clinically to determine the degree of drug efficacy [19, 25, 26] . Therefore, these data suggest that MK-2206 may not only inhibit carcinoid tumor cell growth but may also alleviate the symptoms associated with bioactive hormone production. Therefore, MK-2206 may be a therapeutic option for palliation of carcinoid syndrome symptomatology in addition to reducing tumor burden.
The antitumor effect of MK-2206 was due to its ability to initiate apoptosis and reduce the expression of the prosurvival protein Mcl-1 along with proteins classified as inhibitors of apoptosis (IAP), which include XIAP and survivin. Recent evidence has supported the oncogenic role of the protein survivin, which has been described to be highly expressed in several tumors types [27] . The clinicopathological significance of survivin is inextricably linked to its ability to inhibit the apoptotic cascade in various cancerous tissues, and even more importantly, to confer chemoresistance to cancer cells in the presence of certain anticancer drugs. In fact, recent evidence has implicated the presence of high levels of survivin in the metastatic potential of carcinoid tumors, indicating that this protein, among others, is a reliable indicator of carcinoid tumor burden [28] . Similarly, expression levels of XIAP have been shown to be frequently elevated in certain cancer types, and as often responsible for the development of chemoresistance in cancer patients [29] [30] [31] . Finally, the role of Mcl-1 as a protector from apoptotic cascades in carcinoids has also been well characterized, as its expression has been found to be significantly elevated in panels of human carcinoid specimens of pancreatic and bronchopulmonary origin, which, not surprisingly, showed low levels of apoptotic markers [32] . The ability of MK-2206 to exert its cytotoxic effects in carcinoid cells, in addition to reducing levels of survivin, XIAP, and Mcl-1, indicates that this drug may be capable of counteracting cancer cell defense mechanisms against druginduced cytotoxicity. Because carcinoid patients are often subject to extended periods of chemotherapy, they may have an increased likelihood of developing refractoriness to certain chemotherapeutic agents. Therefore, at present, we can only speculate that MK-2206 has the potential to sensitize chemoresistant carcinoid cell lines. Further studies are required to confirm our hypothesis.
Conclusion
MK-2206 presents a viable option for reducing carcinoid tumor burden and symptomatology, given its ability to reduce carcinoid cell proliferation, neuroendocrine biomarker expression, and prosurvival signals in vitro. Thus, it is important to further explore the use of this compound in preclinical studies and clinical trials on carcinoid patients.
